Childhood Non-Hodgkin's Lymphoma

The third most common childhood cancer is lymphoma; it accounts for 10% of all childhood cancer diagnoses. Of these diagnoses, about 60% are Non-Hodgkin’s Lymphomas. Children are vulnerable to the same types of lymphoma as adults. Although diagnosis of lymphoma in a child is especially traumatic for everyone involved, it must be remembered that younger patients generally have higher recovery rates than adults. This page briefly outlines non-Hodgkin's lymphoma; please use the numerous hyperlinks for more in depth information.

Non-Hodgkin’s Lymphoma (NHL) is a cancerous growth of B-cells or T-cells in the lymphatic system. There are four main types that occur in children:

[More on childhood NHL statistics from ACS]

Symptoms and Diagnosis

Lymphomas present a wide range of symptoms, all of which can indicate less severe conditions. However, if you or your child exhibits several of these symptoms, an appointment with a doctor would be wise.

  • Swelling of the lymph nodes in the neck, underarm, or groin. Swelling is usually painless.
  • Fever
  • Weight loss
  • Fatigue
  • Night sweats
  • Shortness of breath

A diagnosis is made after several tests are conducted, including:

  • Physical examination
  • Chest X-ray
  • Biopsy of a Lymph Node
  • Bone Marrow Biopsy
  • CT Scan
  • Blood Tests
  • Ultrasound

Staging

The general staging rules for NHL are:

Stage I
Involvement of one lymph node group or one area outside the lymph nodes
Stage II
There are two groups of lymph nodes involved on the same side of the diaphragm, or there is one lymph group and one non-lymphatic organ involved. Alternatively, if the lymphoma started in the stomach it is considered Stage II.
Stage III
Tumors occur in lymph groups on both sides of the diaphragm, or began in the chest or abdomen. Also, if the tumors occur around the spine, it is considered Stage III.
Stage IV
This stage is categorized by the involvement of the bone marrow or brain.

Treatments

Typical NHL treatments include

  • Chemotherapy
  • Radiation
  • Stem Cell Transplant
  • Clinical Trials
  • Monoclonal antibodies, such as Rituxan

Late Effects

After treatment, a child's health may still be affected by health problems that show up after cancer treatment (sometimes years later). These are known as a "late effects." For this reason, your child's health must be closely monitored throughout the remainder of their lives. For more information, see the American Cancer Society's Childhood Cancer: Late Effects of Cancer Treatment.

Dive Deeper

Related Articles

Non-Hodgkin's Lymphoma

Resources

Photo by Jyn Meyer

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap